Italian firm claims to have developed coronavirus vaccine
06 May 2020
A team of scientists at Italian medical firm Takis claims to have conducted tests on a mice which, after a single vaccination, developed antibodies that can block the virus from infecting human cells, ANSA reported.
According to tests carried out at Rome’s infectious-disease Spallanzani Hospital, the vaccine has antibodies generated in mice that work on human cells, the Italian news agency reported.
Tests conducted on mice by a team of scientists at Italian medical firm Takis showed they developed antibodies after a single vaccination that can block the virus from infecting human cells, the report said.
A Covid-19 candidate vaccine had neutralised the virus in human cells for the first time, the report quoted Luigi Aurisicchio, CEO of Takis, as saying.
“According to Spallanzani Hospital, as far as we know we are the first in the world so far to have demonstrated a neutralisation of the coronavirus by a vaccine. We expect this to happen in humans too,” Aurisicchio told ANSA.
After observing that five candidate vaccines generated a large number of antibodies, researchers selected the two with the best results.
All of the candidate vaccines currently being developed are based on the material genetic of DNA protein “spike”. They are injected with “electroporation” technique, which consists of an intramuscular injection followed by a brief electrical impulse, helping the vaccine enter the cells.
Researchers at Takis believe that this makes their vaccine particularly effective for generating antibodies in the lung cells, which are the most vulnerable to coronavirus, ANSA reported.